- NZ$43.70m
- NZ$146.98m
- NZ$204.34m
- 54
- 94
- 13
- 56
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 40.19 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.29 | ||
| Price to Tang. Book | 0.3 | ||
| Price to Free Cashflow | 2.59 | ||
| Price to Sales | 0.22 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.95% | ||
| Return on Equity | -41.69% | ||
| Operating Margin | -39.4% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NZ$m | 195.91 | 191.73 | 208.91 | 234.19 | 204.34 | 201.47 | 211.46 | 3.61% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +29.29 | -85.68 | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Comvita Limited is engaged in manufacturing and marketing nature health products, apiary ownership and native forest management. It is also involved in research, manufacturing and distributing manuka honey, bee products, and olive leaf products. It segments include Greater China, Australia, and New Zealand (ANZ), Rest of Asia, North America, and Europe, Middle East, and Africa (EMEA). Its product category includes Kids Health, Manuka Honey, Medihoney, Olive Leaf Extract, Oral Care, Propolis, Bundle Packs, Elixirs and Lozenges, and Gourmet Honey. Its products under Kids Health include Children's Manuka Honey Elixir, Kids Honey, and Kids Day-time Soother Bundle, and others. Its products under Manuka Honey include Manuka Lovers Luxury Pack, Manuka Blend Honey, and Manuka Blend Honey MGO, and others. Medihoney Wound Gel is its Medihoney product. Its Olive Leaf Extract products include Manuka Honey Lozenges Olive Leaf Extract and Manuka Honey Lozenges Olive Leaf Extract 12 Lozenges.
Directors
- Brett Hewlett NEC
- David Banfield CEO
- Nigel Greenwood CFO
- Andy Chen CEX
- Colin Baskin COO
- Corey Blick GMG
- Adrian Barr OTH
- Holly Brown OTH
- Tracy Brown OTH
- Jackie Evans OTH
- Saada McNamee OTH
- Nicola O'Rourke OTH
- Guangping Zhu DRC
- Wu Yawen NED
- Lucas Bunt IND
- Bridget Coates IND
- Sarah Jane Kennedy IND
- Bob Major IND
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 21st, 1974
- Public Since
- November 14th, 2003
- No. of Shareholders
- 2,767
- No. of Employees
- 559
- Sector
- Food & Tobacco
- Industry
- Consumer Defensives
- Exchange
New Zealand Stock Exchange- Shares in Issue
- 70,480,761
- Address
- Private Bag 1, TE PUKE, 3153
- Web
- https://www.comvita.com/
- Phone
- +64 75331426
- Auditors
- KPMG
Upcoming Events for CVT
Similar to CVT
A2 Milk
New Zealand Stock Exchange
Fonterra Co-Operative
New Zealand Stock Exchange
Livestock Improvement
New Zealand Stock Exchange
My Food Bag
New Zealand Stock Exchange
New Zealand King Salmon Investments
New Zealand Stock Exchange
FAQ
What is the Comvita share price?
As of Today at 20:02 UTC, shares in Comvita are trading at NZ$0.62. This share price information is delayed by 15 minutes.
How has the Comvita share price performed this year?
Shares in Comvita last closed at NZ$0.62 and the price had moved by -70.62% over the past 365 days. In terms of relative price strength the Comvita share price has underperformed the ASX All Ordinaries Index by -71.06% over the past year.
What are the analyst and broker recommendations for Comvita?
The overall consensus recommendation for Comvita is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Comvita dividend yield?
Comvita does not currently pay a dividend.
Does Comvita pay a dividend?
Comvita does not currently pay a dividend.
When does Comvita next pay dividends?
Comvita does not currently pay a dividend.
How do I buy Comvita shares?
To buy shares in Comvita you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Comvita?
As of the previous close price of NZ$0.62, shares in Comvita had a market capitalisation of NZ$43.70m.
Where are Comvita shares listed?
Here are the trading details for Comvita:
- Country of listing: New Zealand
- Exchange: NZC
- Ticker Symbol: CVT
What kind of share is Comvita?
Based on an overall assessment of its quality, value and momentum Comvita is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Comvita share price forecast for 2025?
The analyst consensus target price for shares in Comvita is NZ$0.82. That is 33.06% above the last closing price of NZ$0.62.
Analysts covering Comvita currently have a consensus Earnings Per Share (EPS) forecast of -NZ$0.09 for the next financial year.
Find out moreWhat is the trend in the Comvita share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Comvita. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -43.52%.
As of the last closing price of NZ$0.62, shares in Comvita were trading -35.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Comvita PE Ratio?
The Comvita PE ratio based on its reported earnings over the past 12 months is 40.19. The shares last closed at NZ$0.62.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Comvita?
Comvita's management team is headed by:
- Brett Hewlett - NEC
- David Banfield - CEO
- Nigel Greenwood - CFO
- Andy Chen - CEX
- Colin Baskin - COO
- Corey Blick - GMG
- Adrian Barr - OTH
- Holly Brown - OTH
- Tracy Brown - OTH
- Jackie Evans - OTH
- Saada McNamee - OTH
- Nicola O'Rourke - OTH
- Guangping Zhu - DRC
- Wu Yawen - NED
- Lucas Bunt - IND
- Bridget Coates - IND
- Sarah Jane Kennedy - IND
- Bob Major - IND